Articles

  • 1 month ago | stockhead.com.au | Bevis Yeo |Gregor Stronach |Eddy Sunarto |Reuben Adams

    Stockhead is providing factual information where there is a reasonable likelihood of doubt. The information is not intended to imply any recommendation or opinion about a financial product. A note about relevant advertising We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. This is also known as Online Behavioural Advertising.

  • 2 months ago | stockhead.com.au | Tim Boreham |Gregor Stronach |Eddy Sunarto |Reuben Adams

    Stockhead is providing factual information where there is a reasonable likelihood of doubt. The information is not intended to imply any recommendation or opinion about a financial product. A note about relevant advertising We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. This is also known as Online Behavioural Advertising.

  • 2 months ago | stockhead.com.au | Eddy Sunarto |Gregor Stronach |Bevis Yeo |Reuben Adams

    Antares Metals (AM5) is a diversified multi-commodity explorer with two strategic hubs located adjacent to established mine and process infrastructure. In 2024, the Company acquired a highly prospective portfolio of Copper and Uranium tenements in Mt Isa with exploration underway. The Company’s other project, the Carlingup Nickel and Lithium Project in Western Australia, is located ~10km from Arcadium Lithium’s Mt Cattlin Mine, with multiple targets for assessment as commodity prices improve.

  • 2 months ago | stockhead.com.au | Reuben Adams

    The share price of African gold explorer Golden Rim is at its highest level since September last year, after fresh high-grade gold was unearthed right next to an existing 1.4moz ounce resource. Golden Rim’s (ASX: GMR) share price tore up 30 per cent to 2.3c on the announcement, which helps pare some of its losses over the past year.

  • 2 months ago | stockhead.com.au | Reuben Adams

    ASX SMALL CAP WINNERS:Opthea (ASX:OPT) +153% A one-day gain of 148 per cent this week makes Opthea easily the best-performing small cap health or biotech stock on the ASX, at a time when the majority are trending downwards. On Wednesday, the company announced that its OPT-302 drug had worked in a Phase II clinical trial in patients with wet age-related macular degeneration (AMD). CEO Megan Baldwin told a broker gathering the trial results were “just the start”.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Coverage map

X (formerly Twitter)

Followers
274
Tweets
369
DMs Open
No
Reuben Adams
Reuben Adams @reubenadams6
4 Apr 24

RT @StockheadAU: Oh hey! Here’s something new… It’s Stockhead’s Top 10 @ 11 video, featuring 4 #ASX stocks at 1230 (AEDT), because life’s n…

Reuben Adams
Reuben Adams @reubenadams6
8 Jan 24

RT @StockheadAU: Steve Parsons, Ray Shorrocks, Michael Naylor, and Kevin Tomlinson are looking for a @BellevueGold (#ASX:$BGL)-like payday…

Reuben Adams
Reuben Adams @reubenadams6
19 Dec 23

Canada Unearthed: The quest for a #uranium ‘supergiant’ @ForumEnergyMC up ~110% since August on drilling success at Thelon, where "the grades are exceptional, only rivalled by the highest-grade basement-hosted deposits in the Athabasca Basin.” #TSX https://t.co/aAN7X5YnsR